Glazer Capital LLC Purchases Shares of 17,999 Boston Scientific Corporation $BSX

Glazer Capital LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, Holdings Channel reports. The fund purchased 17,999 shares of the medical equipment provider’s stock, valued at approximately $768,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Kelleher Financial Advisors bought a new position in Boston Scientific in the second quarter worth approximately $25,000. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter valued at $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific during the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in shares of Boston Scientific in the 4th quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in Boston Scientific in the 1st quarter worth $28,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

BSX has been the topic of several analyst reports. Royal Bank Of Canada lowered their target price on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, July 30th. Citigroup decreased their price objective on Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Oppenheimer cut their price objective on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research note on Monday, July 27th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $60.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Director Susan E. Morano reportedly purchased additional Boston Scientific shares, signaling confidence from an insider while the stock is near its recent lows. Top Boston Scientific Insider Makes Bold New Share Grab
• Neutral Sentiment: The company’s latest quarterly results had been stronger than expected, with adjusted EPS and revenue exceeding consensus estimates and revenue rising year over year. However, that earnings momentum may provide limited near-term support while the cyber incident remains unresolved.
• Negative Sentiment: Boston Scientific said the cyberattack disrupted information systems used to process customer orders and ship products worldwide. The company is working to restore access, but the timing of a full recovery remains unclear, raising the risk of shipment delays, lost sales, remediation costs and weaker near-term results. Boston Scientific hit by cyberattack, global operations affected
• Negative Sentiment: The cybersecurity disruption comes alongside reports of a cardiac-device recall, increasing investor concerns about operational reliability, regulatory exposure and pressure on Boston Scientific’s growth outlook. The company has not yet quantified the financial impact of either issue. Boston Scientific hit with cardiac device recall

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by company insiders.

Boston Scientific Trading Down 3.2%

Shares of BSX stock opened at $46.64 on Friday. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The firm has a market capitalization of $67.59 billion, a PE ratio of 18.88, a PEG ratio of 1.05 and a beta of 0.56. The stock has a fifty day simple moving average of $46.53 and a two-hundred day simple moving average of $56.72.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period last year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has authorized a stock buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.